Publications by authors named "J Desrame"

Claim this Profile
P
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study.
Camille Evrard, Antoine Pelras, Simon Rivet, Jean-Baptiste Bachet, Olivier Dubreuil, Jérome Desrame

Oncologist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.
David Tougeron, Christophe Louvet, Jérôme Desramé, Ludovic Evesque, Antoine Angelergues

Commun Med (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up.
Maxime K Collard, Laurent Mineur, Célia Nekrouf, Quentin Denost, Philippe Rouanet, Jérôme Desrame

Dis Colon Rectum· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
Emeric Boisteau, Laetitia Dahan, Nicolas Williet, Karine Le Malicot, Jérôme Desramé

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, Ludovic Evesque, Denis Smith

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis